• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胰头癌患者行胰十二指肠切除术时的门静脉切除

Portal vein resection in patients undergoing pancreatoduodenectomy for carcinoma of the pancreatic head.

作者信息

Allema J H, Reinders M E, van Gulik T M, van Leeuwen D J, de Wit L T, Verbeek P C, Gouma D J

机构信息

Department of Surgery, Academic Medical Centre, Amsterdam, The Netherlands.

出版信息

Br J Surg. 1994 Nov;81(11):1642-6. doi: 10.1002/bjs.1800811126.

DOI:10.1002/bjs.1800811126
PMID:7827892
Abstract

Of 176 patients with carcinoma of the pancreatic head region 156 underwent standard pancreatoduodenectomy (group 2) and 20 with macroscopic suspicion of invasion of the portal vein or superior mesenteric vein (SMV) underwent pancreatoduodenectomy with partial resection of the portal vein or SMV (group 1). In 16 patients in group 1 end-to-end anastomosis was used for reconstruction of the vein. The morbidity rate in groups 1 and 2 was similar (55 versus 63 per cent). The hospital mortality rate was 15 per cent in group 1 and 7 per cent in group 2 (P = 0.22). Histological examination confirmed tumour invasion of the portal vein or SMV in ten patients in group 1. Invasion of the portal vein or SMV was significantly more frequent in patients with pancreatic cancer than in those with distal bile duct or ampullary carcinoma. Of the 20 patients in group 1 only three underwent curative resection with tumour-free margins. The median survival time after resection of the portal vein or SMV was 8 months; the 2-year survival rate was 19 per cent. Comparison of survival in group 1 with survival in subgroups of patients undergoing standard pancreatoduodenectomy, matched for all histological parameters, showed no significant difference. It is concluded that partial resection of the portal vein or SMV in patients undergoing pancreatoduodenectomy who are suspected of having tumour invasion of the portal vein or SMV does not improve either the rate of curative resection or survival.

摘要

在176例胰头区域癌患者中,156例行标准胰十二指肠切除术(第2组),20例肉眼怀疑门静脉或肠系膜上静脉(SMV)受侵者行门静脉或SMV部分切除的胰十二指肠切除术(第1组)。第1组中有16例患者行静脉端端吻合重建。第1组和第2组的发病率相似(分别为55%和63%)。第1组的医院死亡率为15%,第2组为7%(P = 0.22)。组织学检查证实第1组中有10例患者肿瘤侵犯门静脉或SMV。胰腺癌患者门静脉或SMV受侵明显比远端胆管癌或壶腹癌患者更常见。第1组的20例患者中只有3例行切缘无肿瘤的根治性切除。门静脉或SMV切除后的中位生存时间为8个月;2年生存率为19%。将第1组的生存率与所有组织学参数匹配的标准胰十二指肠切除术患者亚组的生存率进行比较,未显示出显著差异。得出的结论是,对于怀疑门静脉或SMV有肿瘤侵犯而行胰十二指肠切除术的患者,门静脉或SMV部分切除并不能提高根治性切除率或生存率。

相似文献

1
Portal vein resection in patients undergoing pancreatoduodenectomy for carcinoma of the pancreatic head.胰头癌患者行胰十二指肠切除术时的门静脉切除
Br J Surg. 1994 Nov;81(11):1642-6. doi: 10.1002/bjs.1800811126.
2
Portal or superior mesenteric vein resection in pancreatoduodenectomy for pancreatic head carcinoma.胰头癌胰十二指肠切除术中门静脉或肠系膜上静脉切除。
Br J Surg. 2015 Jun;102(7):837-46. doi: 10.1002/bjs.9799. Epub 2015 Apr 15.
3
Long-term outcomes following en bloc resection for pancreatic ductal adenocarcinoma of the head with portomesenteric venous invasion.胰头导管腺癌伴门静脉肠系膜静脉侵犯整块切除术的长期结果。
Asian J Surg. 2021 Jan;44(1):313-320. doi: 10.1016/j.asjsur.2020.07.021. Epub 2020 Sep 21.
4
Long-term outcome of portomesenteric vein invasion and prognostic factors in pancreas head adenocarcinoma.胰头腺癌门静脉肠系膜静脉侵犯的长期预后及预后因素
ANZ J Surg. 2015 Apr;85(4):264-9. doi: 10.1111/ans.12502. Epub 2014 Feb 12.
5
Clinical significance of portal-superior mesenteric vein resection in pancreatoduodenectomy for pancreatic head cancer.胰头癌胰十二指肠切除术中门静脉-肠系膜上静脉切除的临床意义。
Pancreas. 2012 Jan;41(1):102-6. doi: 10.1097/MPA.0b013e318221c595.
6
Benefit of portal or superior mesenteric vein resection with adjuvant chemotherapy for patients with pancreatic head carcinoma.门静脉或肠系膜上静脉切除联合辅助化疗治疗胰头癌患者的获益。
J Surg Oncol. 2013 Mar;107(4):414-21. doi: 10.1002/jso.23229. Epub 2012 Aug 6.
7
Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection.肠系膜上静脉-门静脉切除的胰十二指肠切除术后的术后发病率和长期生存率。
J Gastrointest Surg. 2006 Sep-Oct;10(8):1106-15. doi: 10.1016/j.gassur.2006.04.002.
8
Safety and efficacy of cryopreserved homologous veins for venous reconstruction in pancreatoduodenectomy.冷冻保存的同种异体静脉在胰十二指肠切除术中用于静脉重建的安全性和有效性。
Surgery. 2017 Feb;161(2):385-393. doi: 10.1016/j.surg.2016.08.016. Epub 2016 Oct 7.
9
Resection of portal and/or superior mesenteric vein and reconstruction by using allogeneic vein for pT3 pancreatic cancer.pT3期胰腺癌门静脉和/或肠系膜上静脉切除及同种异体静脉重建术
J Gastroenterol Hepatol. 2016 Aug;31(8):1498-503. doi: 10.1111/jgh.13299.
10
Segmental resection and wedge excision of the portal or superior mesenteric vein during pancreatoduodenectomy.胰十二指肠切除术中门静脉或肠系膜上静脉的节段性切除和楔形切除。
Surgery. 2001 Feb;129(2):158-63. doi: 10.1067/msy.2001.110221.

引用本文的文献

1
Portal vein reconstruction with bovine pericardium: a comparative analysis of postoperative outcomes in pancreatic surgery.牛心包用于门静脉重建:胰腺手术术后结果的比较分析
Langenbecks Arch Surg. 2025 Apr 3;410(1):118. doi: 10.1007/s00423-025-03689-6.
2
Most oncological pancreas resections must consider the mesopancreas.大多数肿瘤性胰腺切除术必须考虑中胰腺。
BMC Cancer. 2025 Feb 4;25(1):200. doi: 10.1186/s12885-025-13599-x.
3
Pancreatectomy with En Bloc Superior Mesenteric Vein and All Its Tributaries Resection without PV/SMV Reconstruction for "Low" Locally Advanced Pancreatic Head Cancer.
对于“低位”局部进展期胰头癌,行整块切除肠系膜上静脉及其所有属支的胰十二指肠切除术,无需门静脉/肠系膜上静脉重建。
Cancers (Basel). 2024 Jun 15;16(12):2234. doi: 10.3390/cancers16122234.
4
Robotic Vascular Resection in Pancreatic Ductal Adenocarcinoma: A Systematic Review.胰腺导管腺癌的机器人血管切除术:一项系统评价
J Clin Med. 2024 Mar 29;13(7):2000. doi: 10.3390/jcm13072000.
5
Developments in pancreatic cancer surgery.胰腺癌手术的进展。
Updates Surg. 2024 Jan;76(1):17-22. doi: 10.1007/s13304-023-01692-4. Epub 2023 Nov 9.
6
Comprehensive multimodal management of borderline resectable pancreatic cancer: Current status and progress.可切除边缘胰腺癌的综合多模式管理:现状与进展
World J Gastrointest Surg. 2023 Feb 27;15(2):142-162. doi: 10.4240/wjgs.v15.i2.142.
7
A Paradigm Shifts: Neoadjuvant Therapy for Clearly Resectable Pancreatic Cancer.范式转变:可明显切除的胰腺癌的新辅助治疗。
Ann Surg Oncol. 2023 Jun;30(6):3427-3436. doi: 10.1245/s10434-023-13281-1. Epub 2023 Mar 4.
8
Pre-Operative MDCT Staging Predicts Mesopancreatic Fat Infiltration-A Novel Marker for Neoadjuvant Treatment?术前多层螺旋CT分期能否预测胰中脂肪浸润——一种新辅助治疗的新型标志物?
Cancers (Basel). 2021 Aug 28;13(17):4361. doi: 10.3390/cancers13174361.
9
Superior Mesenteric Vein Resection Followed by Porto-Jejunal Anastomosis During Pancreatoduodenectomy for Borderline Resectable Pancreatic Cancer - A Case Report and Literature Review.胰十二指肠切除术治疗边界可切除胰腺癌中肠系膜上静脉切除及门腔空肠吻合术:病例报告及文献复习。
In Vivo. 2021 Sep-Oct;35(5):2975-2979. doi: 10.21873/invivo.12592.
10
Feasibility of mesentericoportal vein reconstruction by autologous falciform ligament during pancreaticoduodenectomy-cohort study.胰十二指肠切除术中利用自体镰状韧带重建肠系膜门静脉可行性:一项队列研究。
BMC Surg. 2021 Jan 4;21(1):4. doi: 10.1186/s12893-020-01019-9.